GSK's Pandemrix problems rumble on
This article was originally published in Scrip
Executive Summary
UK media reports suggesting that the British government is preparing to pay out £1m each to an alleged 60 patients who developed narcolepsy following administration of Pandemrix, have once again turned the spotlight onto the rare adverse event. GlaxoSmithKline – which produced Pandemrix – declined to comment on the latest reports but appears to have shifted slightly from its position a year ago that data were "insufficient" to assess the likelihood of a causal association between Pandemrix and narcolepsy (scripintelligence.com, 27 February 2013).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.